RMC No. 72-2023: Updated VAT-Exempt Medicines List for Cancer, Diabetes, Hypertension and Other Conditions

RMC No. 72-2023 updates the VAT-exempt medicines list, affecting cancer, diabetes, hypertension and other medicines sold by healthcare businesses. Pharmacies, hospitals, clinics, medicine distributors, and VAT-registered healthcare businesses must immediately review whether their medicine master lists, point-of-sale systems, invoices, and tax coding reflect the latest FDA-endorsed updates to the VAT-exempt medicines list. RMC No. 72-2023 […]

RMC No. 124-2022: VAT-Exempt Medicines Updated for Cancer, Tuberculosis, Mental Illness, Diabetes, and Hypertension Under CREATE

RMC No. 124-2022 updates VAT-exempt medicines under CREATE for cancer, tuberculosis, mental illness, diabetes, and hypertension based on FDA publication. Businesses selling, importing, prescribing, dispensing, accounting for, or claiming VAT treatment on covered medicines must check the updated VAT-exempt medicine list immediately because the exemption applies based on the date the Food and Drug Administration […]

RMC No. 34-2019: Input Tax Reporting Rules for VAT-Exempt Diabetes, High-Cholesterol, and Hypertension Medicines

RMC No. 34-2019 explains how sellers of VAT-exempt diabetes, cholesterol, and hypertension medicines must inventory stocks and adjust input tax. Manufacturers, wholesalers, distributors, and retailers holding unsold diabetes, high-cholesterol, and hypertension medicines as of December 31, 2018 had to inventory those medicines and adjust the related input VAT once the medicines became VAT-exempt beginning January […]

RMC No. 2-2019: VAT Exemption on Diabetes, High-Cholesterol and Hypertension Drugs in the Philippines

RMC No. 2-2019 implements VAT exemption for FDA-listed diabetes, high-cholesterol, and hypertension drugs, with EDPMS and price reporting rules. Drug manufacturers, distributors, wholesalers, retailers, hospital pharmacies, and other FDA-licensed establishments must apply VAT exemption only to qualified diabetes, high-cholesterol, and hypertension medicines in final form, and only when those medicines are included in the FDA-published […]

RR No. 25-2018: VAT Exemption on Diabetes, High Cholesterol, and Hypertension Medicines Starting January 1, 2019

RR No. 25-2018 exempts FDA-listed diabetes, cholesterol, and hypertension medicines from VAT on local sale starting January 1, 2019. Starting January 1, 2019, businesses selling covered medicines for diabetes, high cholesterol, and hypertension must treat qualified sales as VAT-exempt, but only if the drug or medicine is included in the official VAT-exempt list identified and […]